Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation

Journal of Hepatology

Volumn 46, Issue 3, 2007, Pages 459-465

  Picciotto, Francesco Paolo ^a   Tritto, Giovanni ^a   Lanza, Alfonso Galeota ^a   Addario, Luigi ^a   De Luca, Massimo ^a   Di Costanzo, GiovanGiuseppe ^a   Lampasi, Filippo ^a   Tartaglione, Maria Teresa ^a   Marsilia, Giuseppina Marino ^a   Calise, Fulvio ^a   Cuomo, Oreste ^a   Ascione, Antonio ^a  

^a CARDARELLI HOSPITAL   (Italy)

Author keywords

Antiviral therapy; Hepatitis C virus; Liver transplantation; Pegylated interferon; Ribavirin

Indexed keywords

CYCLOSPORIN; HEPATITIS B ANTIBODY; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2B; RIBAVIRIN; TACROLIMUS;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; AUTOIMMUNITY; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NEUTROPENIA; PREDICTOR VARIABLE; PRIORITY JOURNAL; PRURITUS; REINFECTION; SIDE EFFECT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT PLANNING; TREATMENT RESPONSE; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECURRENCE; RIBAVIRIN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33846589289     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.10.017     Document Type: Article

References (35)

1. Neumann U.P., and Neuhaus P. Course and treatment of recurrent Hepatitis C after liver transplantation. Minerva Gastroentrol Dietol 50 (2004) 61-66
2. Wiesner R.X., Sorrell M., and Villamill F. Report of the first international liver transplant society consensus conference on liver transplantation and hepatitis C. Liver Transpl 9 (2003) S1-S9
3. Berenguer M., Lopez-Labrador F.X., and Wright T.L. Hepatitis C and liver transplantation. J Hepatol 35 (2001) 666-678
4. Testa G., Crippin J.S., Netto G.J., Goldstein R.M., Jennings L.W., Brkic B.S., et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl 6 (2000) 553-561
5. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 9 (2003) S28-S34
6. Gane E.J., Portmann B.C., Naoumov N.V., Smith H.M., Underhill J.A., Donaldson P.T., et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 334 (1996) 815-820
7. Prieto M., Berenguer M., Rayon J.M., Cordoba J., Arguello L., Carrasco D., et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 29 (1999) 250-256
8. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation?. J Hepatol 42 (2005) 448-479
9. Neumann U.P., Berg T., Bahra M., Puhl G., Guckelberger O., Langrehr J.M., et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow up. Transplantation 77 (2004) 226-231
10. Forman L.M., Lewis J.D., Berlin J.A., Feldman H.I., and Lucey M.R. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122 (2002) 889-896
11. Rodriguez-Luna H., and Vargas H.E. Natural history of hepatitis C and outcomes following liver transplantation. Minerva Gastroenterol Dietol 50 (2004) 51-59
12. Morard I., and Negro F. How should we treat recurrent hepatitis C after liver transplantation?. J Hepatol 43 (2005) 462-468
13. Biselli M., Andreone P., Gramenzi A., Lorenzini S., Loggi E., Bonvicini F., et al. Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen. Dig Liver Dis 38 (2006) 27-32
14. Dumortier J., Scoazec J.Y., Chevallier P., and Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 40 (2004) 669-674
15. Moreno Planas J.M., Rubio Gonzalez E., Boullosa Grana E., Garrido Botella A., Barrios Peinado C., Lucena Poza J.L., et al. Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation. Transpl Proc 37 (2005) 2207-2208
16. Mukherjee S. Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation. Transpl Proc 37 (2005) 4403-4405
17. Wright T.L. How can we identify better those with recurrent hepatitis C who will respond to therapy? What are the optimal treatment regimen and treatment duration?. Liver Transpl 9 (2003) S109-S113
18. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
19. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20.
20. McHutchison J.G., Manns M., Patel K., Poynard T., Lindsay K.L., Trepo C., et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123 (2002) 1061-1069
21. Neff G.W., Montalbano M., O' Brien C.B., Nishida S., Safdar K., Bejerano P.A., et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 15 (2004) 1303-1307
22. Rodriguez-Luna H., Khatib A., Sharma P., De Petris G., Williams J.W., Ortiz J., et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alfa2b and ribavirin: an open-label series. Transplantation 77 (2004) 190-194
23. Castells L., Vargas V., Allende H., Bilbao I., Luis Lazaro J., Margarit C., et al. Combined treatment with pegylated interferon (alfa-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 43 (2005) 53-59
24. Ross A.S., Bhan A.K., Pascual M., Thiim M., Benedict Cosimi A., and Chung R.T. Pegylated interferon alfa 2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transpl 18 (2004) 166-173
25. Yedibela S., Schuppan D., Muller V., Schellerer V., Tannapfel A., Hohenberger W., et al. Successful treatment of hepatitis C reinfection with interferon-alfa2b and ribavirin after liver transplantation. Liver Int 25 (2005) 717-722
26. Abdelmalek M.F., Firpi R.J., Soldevila-Pico C., Reed A.I., Hemming A.W., Liu C., et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 10 (2004) 199-207
27. Bizollon T., Ahmed S.N., Radenne S., Chevallier M., Chevallier P., Parvaz P., et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 52 (2003) 283-287
28. Narayanan Menon K.V., Poterucha J.J., El-Amin O.M., Burgart L.J., Kremers W.K., Rosen C.B., et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 8 (2002) 623-629
29. Bizollon T., Pradat P., Mabrut J.Y., Chevallier M., Adham M., Radenne S., et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transpl 5 (2005) 1909-1913
30. Toniutto P., Fabris C., Fumo E., Apollonio L., Caldato M., Avellini C., et al. Pegylated versus standard interferon-alfa in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy. J Gastroenterol Hepatol 20 (2005) 577-582
31. Babatin M., Schindel L., and Burak K.W. Pegylated-interferon alfa 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy. Can J Gastroenterol 19 (2005) 359-365
32. Giostra E., Kullak-Ublick G.A., Keller W., Fried R., Vanlemmens C., Kraehenbuhl S., et al. Ribavirin/interferon-alfa sequential treatment of recurrent hepatitis C after liver transplantation. Transpl Int 17 (2004) 169-176
33. Samuel D., Bizollon T., Feray C., Roche B., Ahmed S.N., Lemonnier C., et al. Interferon-alfa 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 124 (2003) 642-650
34. Stravitz R.T., Shiffman M.L., Sanyal A.J., Luketic V.A., Sterling R.K., Heuman D.M., et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 10 (2004) 850-858
35. Chalasani N., Manzarbeitia C., Ferenci P., Vogel W., Fontana R.J., Voigt M., et al. Pegasys transplant study group. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 41 (2005) 289-298